Clinical trials: Alzheimer's
Amyloid Plaque, Beta-Amyloid
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
- Trial name
- NCT05462106
- Testing
- ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 304 people
- Sponsor
- AC Immune SA
Alzheimer's Disease
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension.
- Trial name
- NCT07094516
- Testing
- VHB937
- Where
- 73 sites in United States, Australia and 13 more
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer Disease
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
The primary objective is to demonstrate that SR57667B at the dose of 4 mg/day, in comparison to placebo, decreases the decline in cognitive performance and the global clinical decline over 1 year in patients with mild to moderate…
- Trial name
- NCT00285025
- Testing
- SR57667B
- Volunteers
- 500 people
- Sponsor
- Sanofi
Alzheimer Disease, Late Onset
BCG and Plasma Amyloid in Non-Demented Adults
BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and Buruli ulcer.
- Trial name
- NCT04449926
- Testing
- Bacillus of Calmette and Guerin (BCG)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
Alzheimer Disease, Healthy Subjects
Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease
- Trial name
- NCT00795730
- Testing
- NSA-789
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
- Trial name
- NCT00555204
- Testing
- ABT-089
- Where
- 42 sites in United States
- Volunteers
- 337 people
- Sponsor
- Abbott
Alzheimer Disease
Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects
This is a randomized, double-blind study of CMS121 or placebo given as single and multiple escalating doses in normal healthy subjects.
- Trial name
- CMS121 (NCT05318040)
- Testing
- CMS121
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Virogenics, Inc.
Alzheimer's Disease
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00710684
- Testing
- SB-742457 15mg, SB-742457 35mg, donepezil 5-10mg
- Where
- 102 sites in United States, Argentina and 7 more
- Volunteers
- 682 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease
This evaluation of the efficacy and safety of AXONA will be a chart review carried out at 16 practices in which AXONA has been prescribed for the treatment of patients with mild-to-moderate AD.
- Trial name
- ACT (NCT01538212)
- Volunteers
- 55 people
- Sponsor
- Cerecin
Alzheimer Disease
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients
The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.
- Trial name
- NCT06079827
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- MaxWell Clinic, PLC
Healthy
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4 inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over…
- Trial name
- NCT02197884
- Testing
- JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease, Mild Cognitive Impairment
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States.
- Trial name
- GERAS-US (NCT02951598)
- Testing
- Florbetapir F 18 PET Scan
- Where
- 77 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969123
- Testing
- Drug: EVP-6124
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 474 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer's Disease
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy.
- Trial name
- NCT00305903
- Testing
- Rivastigmine, memantine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Novartis
Healthy Volunteers, Tauopathies
A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
This is a Phase 1, first-in-human (FIH), double-blinded, placebo-controlled study where healthy subjects are randomly allocated to receive APNmAb005 or placebo.
- Conditions
- Healthy Volunteers, Tauopathies, Alzheimer Disease
- Trial name
- NCT05344989
- Testing
- APNmAb005
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC
Alzheimer Disease
ASURE: Alzheimer Study Using oRal Edaravone
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study in patients with Alzheimer's Disease (AD).
- Trial name
- NCT05323812
- Testing
- TW001
- Where
- 6 sites in Croatia, Netherlands
- Volunteers
- 61 people
- Sponsor
- Treeway B.V.
Alzheimer Disease, Alzheimer Disease, Late Onset
Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease
The purpose of this study is to determine the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT) in patients with mild/moderate Alzheimer's Disease.
- Trial name
- NCT02958930
- Testing
- MemorEM 1000
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroEM Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.